Gender difference in the association between serum uric acid and metabolic dysfunction-associated steatotic liver disease in patients with newly diagnosed type 2 diabetes
- PMID: 40307757
- PMCID: PMC12042553
- DOI: 10.1186/s12876-025-03917-9
Gender difference in the association between serum uric acid and metabolic dysfunction-associated steatotic liver disease in patients with newly diagnosed type 2 diabetes
Abstract
Purpose: To investigate the relationship between serum uric acid (SUA) levels and metabolic dysfunction-associated steatotic liver disease (MASLD) in newly diagnosed type 2 diabetic patients.
Methods: We performed this retrospective research among 1087 inpatients with new-onset type 2 diabetes millitus (T2DM). Data were analyzed according to gender. Then, the populations were stratified according to their body mass index (BMI) levels in men and women, respectively. The physical and biochemical indicators were measured and recorded. The relationship between SUA and MASLD was estimated using logistic regression analysis, and the unadjusted and adjusted odds ratios (ORs) were calculated.
Results: After adjusting for age, BMI, and other components of the metabolic syndrome, SUA was independently associated with MASLD only in men, but not in women. In addition, for men, the SUA levels were independently associated with MASLD in both non-overweight/obesity and overweight/obesity group. However, for women, the SUA levels were independently related to MASLD in non-overweight/obesity group. There was no association between SUA and MASLD in women with overweight/obesity.
Conclusion: In newly diagnosed type 2 diabetic patients, elevated SUA is an independent predictor for the risk of MASLD in males. In females, the relationship between SUA and MASLD may depend on BMI, with significance only in non-overweight/obese individuals.
Keywords: MASLD; Serum uric acid; Sex; Type 2 diabetes.
© 2025. The Author(s).
Conflict of interest statement
Declarations. Ethics approval and consent to participate: The study protocol conforms to the ethical guidelines of the 1975 Declaration of Helsinki (6 th revision, 2008) as reflected in a priori approval by the ethics committees of Qilu Hospital of Shandong University Dezhou Hospital. Written informed consent was provided by each participant. Consent for publication: Informed consent for publication was obtained from each participant included in the study. Competing interests: The authors declare no competing interests.
Figures


Similar articles
-
Serum uric acid as a biomarker for metabolic dysfunction-associated steatotic liver disease: insights from ultrasound elastography in a Chinese cohort.BMC Gastroenterol. 2025 Feb 20;25(1):94. doi: 10.1186/s12876-025-03666-9. BMC Gastroenterol. 2025. PMID: 39979872 Free PMC article.
-
Serum uric acid and mortality in metabolic dysfunction-associated steatotic liver disease: Subgroup differences.Nutr Metab Cardiovasc Dis. 2024 Dec;34(12):2771-2778. doi: 10.1016/j.numecd.2024.09.015. Epub 2024 Sep 21. Nutr Metab Cardiovasc Dis. 2024. PMID: 39433453
-
Serum uric acid may be a mediator of risk factors in metabolic dysfunction associated steatotic liver disease.Scand J Gastroenterol. 2025 Jun;60(6):581-587. doi: 10.1080/00365521.2025.2490994. Epub 2025 Apr 21. Scand J Gastroenterol. 2025. PMID: 40255082
-
Uric acid and diabetes: Is there a link?Curr Pharm Des. 2013;19(27):4930-7. doi: 10.2174/1381612811319270016. Curr Pharm Des. 2013. PMID: 23278493 Review.
-
Type 2 diabetes mellitus and cardiometabolic outcomes in metabolic dysfunction-associated steatotic liver disease population.Diabetes Res Clin Pract. 2024 May;211:111652. doi: 10.1016/j.diabres.2024.111652. Epub 2024 Apr 2. Diabetes Res Clin Pract. 2024. PMID: 38574897 Review.
References
-
- Review T, LaBrecque DR, Abbas Z, et al. World Gastroenterology Organisation global guidelines: Nonalcoholic fatty liver disease and nonalcoholic steatohepatitis. J Clin Gastroenterol. 2014;48:467–73. - PubMed
-
- Eslam M, Newsome PN, Sarin SK, et al. A new definition for metabolic dysfunction-associated fatty liver disease: An international expert consensus statement. J Hepatol. 2020;73(1):202–9. - PubMed
-
- Eslam M, Sarin SK, Wong VW, et al. The Asian Pacifc Association for the Study of the Liver clinical practice guidelines for the diagnosis and management of metabolic associated fatty liver disease. Hepatol Int. 2020;14(6):889–919. - PubMed
-
- Wang TY, Wang RF, Bu ZY, et al. Association of metabolic dysfunction-associated fatty liver disease with kidney disease. Nat Rev Nephrol. 2022;18(4):259–68. - PubMed
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Medical